{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-012266","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.527422+00:00","generated_at":"2026-05-15T09:17:48.194057+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sanara MedTech Q4 revenue $27.5M (+5% YoY); FY25 rev $103.1M (+19%); reaffirms FY26 guidance","bullets":["Net revenue Q4 2025 $27.5M (+5% YoY); excluding $1.8M prior-year BIASURGE hurricane sales, growth was 13%.","Full year 2025 net revenue $103.1M (+19% YoY); net loss from continuing ops narrowed to $0.4M from $1.9M.","Adjusted EBITDA improved to $4.7M (Q4) and $17.0M (FY), vs $4.1M and $9.1M in prior year.","Reaffirmed full year 2026 financial guidance; no specific numbers provided in the release.","BIASURGE received Vizient Innovative Technology contract effective Jan 1, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-012266","json":"https://secwatch.observer/filing/0001493152-26-012266.json","markdown":"https://secwatch.observer/filing/0001493152-26-012266.md","text":"https://secwatch.observer/filing/0001493152-26-012266.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315226012266/0001493152-26-012266-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315226012266/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:17:48.194057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cde29331bdb2a54d4848c2d76b6f4f63625e0e68","claim":"Sanara MedTech Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $27.5 million, net income Net loss from continuing operations of $1.1 million. Guidance reaffirmed.","evidence_excerpt":"December 31, 2025, and reaffirmed its financial guidance for the full year ending December 31, 2026. Fourth Quarter 2025 Financial Summary (1 ) ● Net revenue increased 5% to $27.5 million, compared to $26.3 million in the fourth quarter of 2024. ○ As previously disclosed, the Company experienced growth in sales of BIASURGE ® Advanced Surgical Solution","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/714256/000149315226012266/0001493152-26-012266-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Revenue","value":"$27.5 million"},{"label":"Net income","value":"Net loss from continuing operations of $1.1 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}